Business Description
Moderna Inc
NAICS : 325412
SIC : 2836
Compare
Compare
Traded in other countries / regions
MRNA.USA0A45.UKM1RN34.Brazil0QF.Germany1MRNA.ItalyMRNA.MexicoMRNA.AustriaMRNA_KZ.KazakhstanMRNA.PeruMRNA.Switzerland0QF.Bulgaria IPO Date
2021-11-12Description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.99 |
N/A
|
N/A
| |||
Equity-to-Asset | 0.62 |
N/A
|
N/A
| |||
Debt-to-Equity | 0.19 |
N/A
|
N/A
| |||
Debt-to-EBITDA | -0.46 |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 9.09 | |||||
Beneish M-Score | -3.83 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -52.2 | |||||
3-Year Book Growth Rate | -23.8 |
N/A
|
N/A
| |||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 25.36 |
N/A
|
N/A
| |||
Future 3-5Y Total Revenue Growth Rate Estimate | 17.08 |
N/A
|
N/A
|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 56.49 |
N/A
|
N/A
| |||
9-Day RSI | 63.65 |
N/A
|
N/A
| |||
14-Day RSI | 65.45 |
N/A
|
N/A
| |||
3-1 Month Momentum % | 21.55 |
N/A
|
N/A
| |||
6-1 Month Momentum % | 9.78 |
N/A
|
N/A
| |||
12-1 Month Momentum % | 107.41 |
N/A
|
N/A
|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.29 |
N/A
|
N/A
| |||
Quick Ratio | 2.18 |
N/A
|
N/A
| |||
Cash Ratio | 2.03 |
N/A
|
N/A
| |||
Days Inventory | 49.22 |
N/A
|
N/A
| |||
Days Sales Outstanding | 44.72 |
N/A
|
N/A
| |||
Days Payable | 46.49 |
N/A
|
N/A
|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.8 |
N/A
|
N/A
| |||
Shareholder Yield % | -0.52 |
N/A
|
N/A
|
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 22.76 |
N/A
|
N/A
| |||
Operating Margin % | -150.23 |
N/A
|
N/A
| |||
Net Margin % | -142.58 |
N/A
|
N/A
| |||
EBITDA Margin % | -126.88 |
N/A
|
N/A
| |||
FCF Margin % | -56.29 |
N/A
|
N/A
| |||
OCF Margin % | -48.55 |
N/A
|
N/A
| |||
ROE % | -37.92 |
N/A
|
N/A
| |||
ROA % | -26.73 |
N/A
|
N/A
| |||
ROIC % | -49.53 |
N/A
|
N/A
| |||
3-Year ROIIC % | 143.1 |
N/A
|
N/A
| |||
ROC (Joel Greenblatt) % | -106.49 |
N/A
|
N/A
| |||
ROCE % | -31.22 |
N/A
|
N/A
| |||
Years of Profitability over Past 10-Year | 2 |
N/A
|
N/A
| |||
Moat Score | 7 |
N/A
|
N/A
| |||
Tariff Resilience Score | 4 |
N/A
|
N/A
|
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 27.37 |
N/A
|
N/A
| |||
PB Ratio | 9.1 |
N/A
|
N/A
| |||
Price-to-Tangible-Book | 9.33 |
N/A
|
N/A
| |||
EV-to-EBIT | -18.96 |
N/A
|
N/A
| |||
EV-to-Forward-EBIT | -14.91 |
N/A
|
N/A
| |||
EV-to-EBITDA | -20.59 |
N/A
|
N/A
| |||
EV-to-Forward-EBITDA | -15.94 |
N/A
|
N/A
| |||
EV-to-Revenue | 26.13 |
N/A
|
N/A
| |||
EV-to-Forward-Revenue | 25.44 |
N/A
|
N/A
| |||
EV-to-FCF | -46.41 |
N/A
|
N/A
| |||
Price-to-GF-Value | 6.39 |
N/A
|
N/A
| |||
Price-to-Projected-FCF | 3.27 |
N/A
|
N/A
| |||
| Price-to-Net-Current-Asset-Value | 38.11 |
N/A
|
N/A
| |||
| Price-to-Net-Cash | 65.65 |
N/A
|
N/A
| |||
Earnings Yield (Greenblatt) % | -5.27 |
N/A
|
N/A
| |||
FCF Yield % | -2.02 |
N/A
|
N/A
|
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Moderna Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,210 | ||
| EPS (TTM) ($) | -7.99 | ||
| Beta | N/A | ||
| 3-Year Sharpe Ratio | -0.03 | ||
| 3-Year Sortino Ratio | -0.04 | ||
| Volatility % | 165.52 | ||
| 14-Day RSI | 65.45 | ||
| 14-Day ATR ($) | 12.88 | ||
| 20-Day SMA ($) | 101.28 | ||
| 12-1 Month Momentum % | 107.41 | ||
| 52-Week Range ($) | 25.1 - 165 | ||
| Shares Outstanding (Mil) | 399.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Moderna Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Moderna Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-19 | In 170 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-12 08:00 | In 164 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-12 | In 163 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 08:00 | In 66 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 65 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-31 08:00 | 59.99 (-2.72%) | ||
| Second quarter earnings results for 2026 | 2026-07-31 | 59.99 (-2.72%) | ||
| Moderna Science Day | 2026-06-25 09:00 | 61.69 (+0.37%) | ||
| Guidance call for 2026 | 2026-06-09 15:20 | 47.00 (-0.97%) | ||
| Bernstein\'s 42nd Annual Strategic Decisions Conference | 2026-05-28 10:00 | 48.03 (+0.00%) |
Show
Entries
Moderna Inc Frequently Asked Questions
What is Moderna Inc(XKAZ:MRNA_KZ)'s stock price today?
The current price of XKAZ:MRNA_KZ is $137.20. The 52 week high of XKAZ:MRNA_KZ is $165.00 and 52 week low is $25.10.
When is next earnings date of Moderna Inc(XKAZ:MRNA_KZ)?
The next earnings date of Moderna Inc(XKAZ:MRNA_KZ) is 2026-11-06 Est..
Does Moderna Inc(XKAZ:MRNA_KZ) pay dividends? If so, how much?
Moderna Inc(XKAZ:MRNA_KZ) does not pay dividend.
Press Release
Articles on Moderna Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers